Core Viewpoint - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with a focus on dry age-related macular degeneration (AMD) and geographic atrophy (GA), impacting nearly 10 million people globally [1][8] Company Overview - Annexon is a biopharmaceutical company specializing in immunotherapies aimed at neuroinflammatory diseases [1][8] - The company is developing vonaprument, a C1q inhibitor designed to be the first targeted vision-preserving therapy for GA [6][8] Event Announcement - Annexon will host a key opinion leader (KOL) event in New York on March 18, 2026, featuring presentations on dry AMD and GA [1][2] - The event will include a live Q&A session following the formal presentations [2] Expert Contributions - Dr. Eleonora Lad and Dr. Charles C. Wykoff will present at the event, focusing on the unmet needs in GA treatment and the mechanism of disease [5] - Dr. Lad's research includes the role of neuroinflammation in AMD and the development of innovative diagnostic approaches [3] - Dr. Wykoff has extensive experience in clinical trials and research related to retinal diseases [4] Product Development - Vonaprument is a clinical-stage investigational therapy that selectively inhibits C1q, aiming to protect retinal function [6] - The drug has received Fast Track designation from the FDA and Priority Medicine designation from the European Medicines Agency [6] Clinical Trial Information - The Phase 3 ARCHER II trial has enrolled over 630 patients with advanced dry AMD and GA, with a primary endpoint of preventing a ≥15-letter loss in best corrected visual acuity [7] - Topline data from the trial is expected in the second half of 2026 [7]

Vonaprument (ANX007) in Geographic Atrophy (GA) - Vonaprument is the only GA program to demonstrate significant vision preservation, representing a potential blockbuster market opportunity[9, 15] - Phase 2 trial (ARCHER) showed significant time and dose-dependent vision preservation in GA patients, with a 73% risk reduction in BCVA ≥15-letter loss at two consecutive visits in the monthly (EM) dosing group (p = 0.0207) compared to sham[29] - In the ARCHER trial, 21.3% of patients in the sham group experienced persistent BCVA ≥15-letter loss through month 12+, compared to 5.6% in the Vonaprument EM group and 9.8% in the Vonaprument EOM group[25] - Photoreceptor protection was numerically greater in the central macula with Vonaprument, showing a 59% decrease in total Ellipsoid Zone (EZ) loss in the central 1.5 mm area compared to sham[34] - ARCHER II Phase 3 program is now fully enrolled with approximately 630 patients randomized in a 2:1 ratio (Vonaprument to Sham), with topline data expected in 2H'26[39] Safety and Clinical Development - ARCHER trial safety data showed Choroidal Neovascularization events in 3.4% of the sham group, 4.5% of the Vonaprument EM group, and 4.3% of the Vonaprument EOM group[36] - Global registration path established supporting potential first approval in both EU and US for dry AMD with GA; PRIME designation in EU[17] Pipeline and Platform - Annexon has a clinically validated scientific platform with broad potential across multiple therapeutic areas[9] - The company is pioneering a scientific approach to stop complement-driven neuroinflammation by blocking C1q[11, 12] - Annexon has a diverse late-stage clinical platform for classical complement-mediated neuroinflammatory diseases of the body, brain, and eye[14]